Stocktoria

Moleculin Biotech, Inc. MBRX

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2016-06-02 · LEI

Moleculin Biotech, Inc. statistics & valuation

Market cap$17.4M
P / B1.2×
Return on capital-164.4%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
2016201720182019202020212022202320242025
Operating margin (%)
2016201720182019202020212022202320242025
Return on equity (%)
-26.20% -57.30% -83.20% -84.80% -97.70% -20.10% -55.60% -96.30% -232.40% -223.60% 2016201720182019202020212022202320242025
Shares outstanding
12.2M 21.5M 28.5M 7.6M 11.5M 28.6M 1.9M 2.2M 137720 3.2M 2016201720182019202020212022202320242025
Net debt ($)
2016201720182019202020212022202320242025
Share buybacks ($)
2016201720182019202020212022202320242025
Return on assets (%)
-23.90% -50.30% -60.60% -52.30% -59.80% -18.90% -50.50% -77.90% -153.90% -151.70% 2016201720182019202020212022202320242025
Free cash flow margin (%)
2016201720182019202020212022202320242025
Debt / equity (×)
2016201720182019202020212022202320242025
EPS ($)
2016201720182019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Return on assets-151.7%-153.9%-77.9%-50.5%-18.9%-59.8%-52.3%-60.6%-50.3%-23.9%
Return on equity-223.6%-232.4%-96.3%-55.6%-20.1%-97.7%-84.8%-83.2%-57.3%-26.2%
Current ratio1.410.973.869.4620.025.893.782.063.753.88

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.